ARK Autonomous Technology & Robotics ETF (ARKQ)
- Previous Close
69.73 - Open
70.15 - Bid 71.76 x 1200
- Ask 71.78 x 1800
- Day's Range
69.50 - 71.94 - 52 Week Range
48.25 - 72.07 - Volume
98,715 - Avg. Volume
73,096 - Net Assets 762.01M
- NAV 69.75
- PE Ratio (TTM) 38.74
- Yield 0.00%
- YTD Daily Total Return 20.85%
- Beta (5Y Monthly) 1.33
- Expense Ratio (net) 0.75%
The fund is an actively-managed exchange-traded fund that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of autonomous technology and robotics companies that are relevant to the fund's investment theme of disruptive innovation. Substantially all of the fund's assets will be invested in equity securities, including common stocks, partnership interests, business trust shares and other equity investments or ownership interests in business enterprises. The fund is non-diversified.
ARK ETF Trust
Fund Family
Technology
Fund Category
762.01M
Net Assets
2014-09-30
Inception Date
Performance Overview: ARKQ
View MoreTrailing returns as of 11/20/2024. Category is Technology.
People Also Watch
Holdings: ARKQ
View MoreTop 10 Holdings (61.49% of Total Assets)
Sector Weightings
Recent News: ARKQ
View More
Research Reports: ARKQ
View MoreCrispr Earnings: Global Casgevy Rollout Underway; Positive Outlook for Risk-Tolerant Investors
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
RatingPrice TargetCrispr Earnings: Positive Long-Term Outlook as Launch of Casgevy is Underway; Shares Undervalued
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.
RatingPrice TargetCrispr Earnings: Commercial Launch of Casgevy Is Underway; Positive Outlook and Shares Undervalued
Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
RatingPrice TargetCrispr Earnings: Commercial Launch of Casgevy Is Underway; Positive Outlook and Shares Undervalued
Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
RatingPrice Target